Research programme: ADAPTIR multi-specific therapeutics - Aptevo Therapeutics

Drug Profile

Research programme: ADAPTIR multi-specific therapeutics - Aptevo Therapeutics

Alternative Names: Anti-CD123 x Anti-CD3; Anti-CD19 X Anti-CD-3; Anti-CD86 X mono-IL-10; Anti-HER2 X Anti-CD3; Anti-RON X Anti-CD3; APVO 210; APVO-425; APVO-436; APVO-437; CD79BxDR; CD79BxDR Scorpion™ molecule; CTLA-4 X mono-IL-10; ES-210; ES-425; ROR1 Bispecific; T-Scorp; TNFR x A2; TNFR x TWEAKR; X1 Anti-TNF-based SCORPION™; X1 TNF-based SCORPION™; X2 CTLA4-based SCORPION™

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trubion Pharmaceuticals
  • Developer Aptevo Therapeutics
  • Class Bispecific antibodies; Proteins; Small molecules
  • Mechanism of Action CD19 antigen inhibitors; CD3 antigen inhibitors; CD79 antigen inhibitors; CD86 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; ERBB 2 receptor antagonists; Glutamate carboxypeptidase II inhibitors; HLA-DR antigen inhibitors; Immunosuppressants; Receptor tyrosine kinase-like orphan receptor antagonists; RON protein inhibitors; TNFSF12 protein inhibitors; Tumour necrosis factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Graft-versus-host disease; Irritable bowel syndrome; Rheumatoid arthritis

Most Recent Events

  • 28 Nov 2017 Aptevo Therapeutics announces intention to submit IND for APVO 210 to US FDA for Autoimmune disorders and Inflammation in 2018
  • 28 Nov 2017 Aptevo Therapeutics announces intention to submit IND for APVO 436 to US FDA for Acute myeloid leukaemia in 2018
  • 30 Oct 2017 Aptevo Therapeutics plans a clinical trial of APVO 436 in the treatment of Acute myeloid leukaemia in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top